A site where you can find recommended contractors for non-clinical testing|effical " Non-Clinical CROs and Agencies " Nemoto Science Co.,Ltd.

Nemoto Science Co.,Ltd.

Nemoto Science Co.,Ltd. is a CRO specializing in contract pharmacokinetic (PK) studies and compound synthesis.This page provides an overview of the company’s non-clinical capabilities, representative study models, and case studies.
We have summarized information below for a reference.

Features of Nemoto Science Co.,Ltd.’s Non-clinical Contract Services

Wide Range of Study Capabilities

Nemoto Science Co.,Ltd. offers a GLP-compliant broad spectrum of studies that span from drug discovery through preclinical development.
The company handles numerous animal species—from small animals(mice and rats) to medium and large species(rabbits and non-human primates) —and offers both in vivo and in vitro studies.

Advanced Technologies and Equipment

Nemoto Science Co.,Ltd. performs detailed analyses using RI tracer studies with a wide range of radioisotopes (14C, 3H, 125I, 32P, 51Cr, etc.) and advanced analytical instruments including LC-MS/MS.
The company has introduced state-of-the-art technologies such as Orbitrap-based analysis of RI-dosed samples and metabolite identification via HPLC on-line LSC.
Specialized technical capabilities

Reliable GLP Compliance

Since the first GLP compliance inspection in 1998, Nemoto Science Co.,Ltd. has received an “A” or “Compliant” rating in every subsequent inspection. All of their studies are conducted at GLP-compliant facilities, enabling the company to generate high-quality and reliable non-clinical data for regulatory submission.

Partnered CROs with Nemoto Science Co.,Ltd.

Mediford Corporation

Mediford offers a comprehensive range of services, such as regulatory safety studies, pharmacology studies, pharmacokinetic studies, and supports exploratory research during the early stages of R&D.
Their facilities are not compliant with pharmaceutical GLP, medical device GLP, regenerative medicine GLP, agricultural chemical GLP, or the Chemical Substances Control Law GLP. Nemoto Science Co.,Ltd. is partnered with Mediford for specialty non-clinical pharmacokinetic studies.

Nemoto Science Co.,Ltd. Non-clinical Case Studies

In Vivo Pharmacokinetic Studies

Nemoto Science Co.,Ltd. offers development-appropriate in vivo PK studies at GLP-compliant facilities. They are capable of handling small animals (mice, rats, guinea pigs) as well as rabbits, dogs, and non-human primates.
Capabilities include RI tracer studies using various isotopes (14C, 3H, 125I, 32P, 51Cr) and analytical studies with LC-MS/MS and related platforms.
Study protocols and final reports can be prepared in both English and Japanese upon request.

Reference: Nemoto Science Co.,Ltd. official website https://www.nemotoscience.co.jp/souyaku

In Vivo PK Studies (Absorption, Distribution, and Excretion)

With decades of expertise in animal experimentation, Nemoto Science Co.,Ltd. provides reproducible and reliable data for absorption, distribution, and excretion studies.
Absorption studies include measurements such as blood and plasma concentration profiles, identification of gastrointestinal absorption sites, and evaluation of portal vein absorption.
For distribution studies, they can provide tissue distribution assessments, micro-autoradiography, placental transfer studies, and plasma protein binding evaluations.
In Excretion studies, urinary, fecal, biliary, and exhaled elimination can be evaluated.

Reference: Nemoto Science Co.,Ltd. official website https://www.nemotoscience.co.jp/souyaku

Company Information

Nemoto Science Co.,Ltd. has performed studies for many pharmaceutical companies for pharmacokinetic studies using tritium-labeled compounds, as well as contract synthesis and testing throughout the discovery and development phases.

Address 4-10-9 Takaido Higashi, Suginami-ku, Tokyo
Tel 03-3333-2711
Website https://www.nemotoscience.co.jp/
3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation
SMC Laboratories, Inc.
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)
  • SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
  • From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.

  • With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.
Safety Studies
Comprehensive Safety Evaluation for FIH Applications
Labcorp Holdings Inc.
(Labcorp Drug Development)
Labcorp Holdings Inc.
Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)
  • Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
  • The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
  • Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.
Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation
PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd.
Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)
  • PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
  • With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.

  • The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

By region
list of animal models
Expertise & Track Record
3 Recommended Contract Non-Clinical Testing Services